Syndax Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Syndax Pharmaceuticals Inc.
Ownership: Public
Status: Active
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: New York
Headquarters state / province: New York
Headquarters country: United States
Fiscal year end: December
Ticker symbol: SNDX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001395937
EIN: 32-0162505

Board of directors

Follow this board

Aleksandra Rizo · Director
Since 2024
Briggs Morrison · Director · President, Head of R&D
Since 2023
Dennis Podlesak · Director
Since 2023
Jennifer Jarrett · Director Overboarded
Since 2023
Keith Katkin · Director
Since 2023
Martin H. Huber Jr. · Director
Since 2023
Michael A. Metzger · Director · Chief Executive Officer
Since 2023
Pierre Legault · Director
Since 2023
William Meury · Director
Since 2023

Chief executives

Michael A. Metzger · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Pierre Legault

63.5%
Michael A. Metzger

98.9%

Board connections

7 of this board's directors also sit on 13 other boards.

Shared director Other board Same sector

Actuate Therapeutics Inc.
via Martin H. Huber Jr.
Arcus Biosciences Inc.
via Jennifer Jarrett
Arvinas Inc.
via Briggs Morrison
Bicycle Therapeutics plc
via Pierre Legault
CRISPR Therapeutics AG
via Briggs Morrison
Damora Therapeutics Inc.
via Jennifer Jarrett
Eledon Pharmaceuticals Inc.
via Keith Katkin
Emergent BioSolutions Inc.
via Keith Katkin
Incyte Corp.
via William Meury
Pyxis Oncology Inc.
via Michael A. Metzger
Sagimet Biosciences Inc.
via Jennifer Jarrett
Werewolf Therapeutics Inc.
via Briggs Morrison
Zura Bio Limited
via Jennifer Jarrett

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $2,749,127; 9 sales by 3 insiders

Date	Insider	Transaction	Shares	Price	Value
Jul 8, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Option exercise	+32,375	$6.38	$206,553
Jul 8, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−32,375	$24.24	$784,776
Jun 12, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Option exercise	+31,235	$13.82	$431,668
Jun 12, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Open-market sale	−31,235	$18.14	$566,603
Jun 11, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Option exercise	+22,515	$13.82	$311,157
Jun 11, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Open-market sale	−34,280	$18.00	$617,040
Jun 1, 2026	Keith A. Goldan Officer (Chief Financial Officer)	Open-market sale	−1,177	$18.99	$22,351
Jun 1, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−6,847	$18.99	$130,025
Feb 9, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−17,159	$21.03	$360,854
Feb 9, 2026	Goldan Keith A. Officer (Chief Financial Officer)	Open-market sale	−3,410	$21.03	$71,712
Feb 6, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−7,412	$20.62	$152,835
Feb 6, 2026	Goldan Keith A. Officer (Chief Financial Officer)	Open-market sale	−2,082	$20.62	$42,931
Feb 4, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Grant or award	+73,000	—	—
Feb 4, 2026	Jennifer Jarrett Director	Grant or award	+24,000	—	—
Feb 4, 2026	Martin H. Huber Jr. Director	Grant or award	+24,000	—	—

Reviews (0)

No reviews yet. Be the first to write one.